Edition:
India

Soligenix Inc (SNGX.OQ)

SNGX.OQ on NASDAQ Stock Exchange Capital Market

1.55USD
1:30am IST
Change (% chg)

$0.01 (+0.65%)
Prev Close
$1.54
Open
$1.54
Day's High
$1.56
Day's Low
$1.53
Volume
2,322
Avg. Vol
21,879
52-wk High
$3.70
52-wk Low
$1.45

Latest Key Developments (Source: Significant Developments)

Soligenix Identifies Biomarkers For Ricin Toxin Vaccine Testing Under FDA Animal Rule
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Soligenix Inc ::SOLIGENIX IDENTIFIES BIOMARKERS FOR RICIN TOXIN VACCINE TESTING UNDER THE FDA ANIMAL RULE.SOLIGENIX INC - BIOMARKERS FOR RICIN TOXIN VACCINE TESTING BEEN SUCCESSFULLY IDENTIFIED, FACILITATING POTENTIAL APPROVAL UNDER FDA "ANIMAL RULE".SOLIGENIX INC - FURTHER EFFICACY STUDIES IN NHPS EVALUATING POTENTIAL DOSING REGIMENS ARE ANTICIPATED IN 2018.SOLIGENIX - RIVAX DEMONSTRATED REDUCED NUMBER OF VACCINATIONS MAY BE REQUIRED TO ESTABLISH PROTECTION, POTENTIALLY UTILIZING ONLY 2 DOSES INSTEAD OF 3.  Full Article

‍Knoll Capital Management LP​ reports a 9.9 pct passive stake in Soligenix as of Nov 2
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Soligenix Inc :‍Knoll Capital Management LP​ reports a 9.9 percent passive stake in Soligenix Inc as of Nov 2 - SEC Filing.  Full Article

‍ACT Capital Management reports 9.9 pct passive stake in Soligenix - SEC filing​
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - ‍ACT Capital Management LLLP::‍act Capital Management LLLP reports 9.9 percent passive stake in Soligenix Inc as of November 2, 2017 - SEC filing​.  Full Article

Soligenix reports Q3 loss per share $0.17
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Soligenix Inc :Soligenix announces recent accomplishments and third quarter 2017 financial results.Q3 loss per share $0.17.Q3 revenue $1.82 million versus $2.96 million.Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.  Full Article

Soligenix Q2 EPS $0.00
Thursday, 11 Aug 2016 

Soligenix Inc : Q2 revenue $3.2 million versus $1.1 million . Soligenix announces recent accomplishments and second quarter 2016 financial results highlighted by revenues of $3.2 million .Q2 earnings per share $0.00.  Full Article

BRIEF-Soligenix Receives Orphan Drug Designation From The European Commission For Rivax For Prevention Of Ricin Poisoning

* SOLIGENIX RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR RIVAX® FOR PREVENTION OF RICIN POISONING Source text for Eikon: Further company coverage: